Logo

ESLAW

Estrella Immunopharma, Inc.

ESLAW

Estrella Immunopharma, Inc. • NASDAQ
$0.10 ▲ 16.47% (+0.01)
Market Cap $3.51 M
52w High $0.14
52w Low $0.10
Dividend Yield 0%
P/E 0
Volume 1.50K
Outstanding Shares 35.42M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $5.544M ▲ $-5.545M ▼ 0% $-0.15 ▼ $-5.544M ▼
Q1-2025 $0 $2.104M ▲ $-2.104M ▼ 0% $-0.058 ▼ $-2.104M ▼
Q4-2024 $0 $1.05M ▼ $-1.05M ▲ 0% $-0.029 ▲ $-1.05M ▲
Q3-2024 $0 $3.377M ▼ $-3.377M ▲ 0% $-0.093 ▲ $-3.377M ▲
Q2-2024 $0 $3.949M $-3.951M 0% $-0.11 $-3.949M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $1.317M ▲ $2.981M ▲ $9.075M ▲ $-6.095M ▼
Q1-2025 $421.473K ▼ $2.444M ▼ $4.275M ▲ $-1.831M ▼
Q4-2024 $916.916K ▼ $3.141M ▼ $2.997M ▲ $143.731K ▼
Q3-2024 $1.798M ▼ $3.735M ▼ $2.989M ▲ $746.286K ▼
Q2-2024 $4.165M $4.454M $180.701K $4.273M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-5.545M ▼ $-414.879K ▲ $0 $1.31M ▲ $895.121K ▲ $-414.879K ▲
Q1-2025 $-2.104M ▼ $-465.981K ▲ $0 $-29.462K ▼ $-495.443K ▲ $-465.981K ▲
Q4-2024 $-1.05M ▲ $-896.066K ▲ $0 $15.479K ▲ $-880.587K ▲ $-896.07K ▲
Q3-2024 $-3.377M ▲ $-2.217M ▼ $0 $-150.465K ▲ $-2.368M ▼ $-2.217M ▼
Q2-2024 $-3.951M $-291.513K $0 $-270.349K $-561.862K $-291.51K

Five-Year Company Overview

Income Statement

Income Statement Estrella is still a pure R&D story with no product sales yet. The income statement is very simple: no revenue and modest but persistent operating losses as the company funds research and early clinical trials. Losses have inched up, which is normal for a clinical‑stage biotech moving from concept toward human studies. The key takeaway is that the business is entirely in investment mode and depends on future success of its pipeline rather than current earnings.

Balance Sheet

Balance Sheet The balance sheet appears very light, reflecting a small, early‑stage company. Reported assets and equity are minimal, with no meaningful debt showing up. This suggests the company is equity‑funded so far, but it also means there is little balance‑sheet cushion. Future growth and survival will likely depend on ongoing access to new capital, as opposed to relying on an existing large asset base or cash pile.

Cash Flow

Cash Flow Cash flows show outflows from operations as the company spends on research, clinical work, and corporate costs, with no offsetting inflows from product sales. Capital spending needs look low so far, but the business still consumes cash. This pattern is typical for a development‑stage biotech: negative operating cash flow, reliance on financing transactions, and a need to manage its cash runway carefully as trials progress.

Competitive Edge

Competitive Edge Competitively, Estrella is operating in a crowded and high‑stakes field—cell therapies for cancer—but is trying to stand out with a platform aimed at being safer and more tolerable than traditional CAR‑T treatments. Its focus on reducing severe side effects and potentially treating patients who are currently too fragile for existing options could carve out a meaningful niche if clinical results continue to support the technology. Partnerships, such as the one targeting solid tumors, add credibility but the company still faces intense competition from larger, better‑funded players in oncology.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Estrella’s story. The ARTEMIS platform is designed to mimic a more natural immune response, which may improve both safety and durability of treatment. Early trial signals in blood cancers appear encouraging, with additional programs targeting dual antigens and solid tumors, plus exploratory work in autoimmune disease. The pipeline is still early, so there is significant scientific and regulatory uncertainty, but the R&D focus is sharp and centered on a differentiated mechanism in a well‑defined medical need.

Summary

Overall, Estrella looks like a classic early‑stage biotech: no revenue, ongoing losses, and a lean balance sheet, offset by a high‑risk, high‑potential technology platform. The company’s value hinges on whether its T‑cell therapies can prove safer and broadly effective in larger, later‑stage trials. Success could open doors in both blood cancers and solid tumors, but setbacks in the clinic or difficulty raising additional capital would be key vulnerabilities. Anyone following the company would likely focus on clinical data milestones, partnership progress, and funding visibility rather than traditional profitability metrics at this stage.